NEWTON, MA and GENEVA, SWITZERLAND – May 25, 2021 – Acer Therapeutics Inc. (Nasdaq: ACER)(“Acer”), a pharmaceutical company focused on the acquisition, development and commercialization of therapies …
News
Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021
COVID Innovations March 25th, 2021
Author: Dr. Linda Morrow – March 25th, 2021 Imagine a pandemic without having to shut down our lives. Imagine governments and industry working cooperatively to develop diagnostic and vaccine …
Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
Relief to potentially pay Acer up to $36 million and royalties in exchange for net profit share and territory rights ACER-001 pre-NDA meeting with U.S. FDA scheduled in Q2 2021 GENEVA, SWITZERLAND and …
Access Vascular, Inc. Secures $20 Million in Series B Financing
Bedford, MA – 03 March, 2021- Access Vascular, Inc., a company addressing the most common and costly venous access complications, today announced it has closed on a Series B round of financing. …
Kent’s deal with Net Health to expand Snapshot’s footprint
By David Godkin, Staff WriterTORONTO – Think of it. More than 14,000 facilities boasting 98% of the largest hospital chains across the U.S., two-thirds of skilled nursing facilities and hospice …
TVM Life Science Innovation II SCSp Announces Investment in Vespina Lifesciences Inc.
Luxembourg, February 1st, 2021 – TVM Life Science Innovation II SCSp today announced the Fund’s investment establishing Vespina Lifesciences Inc., a company based in Newark, Delaware. Vespina …